Navigation Links
Laura Bush in Senegal for Anti-HIV/AIDS, Malaria Campaigns

The First Lady of the United States, Laura Bush arrived in the Senegalese capital of Dakar Monday at the start of a four-nation Africa tour to bolster the US government's anti AIDS and malaria strategies.

She was met at the airport by President Abdoulaye Wade's wife Viviane.

From Senegal she is due to travel to nearby Mali then Zambia and Mozambique during a five-day long trip to the continent which will also focus on education and women's empowerment.

She is due to visit US-funded 15 billion dollar projects under the President's Emergency Program for AIDS Relief (PEPFAR), which was launched by President George W. Bush in 2003 and is due to expire in September 2008.

Bush last month asked Congress to set aside 30 billion dollars over five years to fight AIDS worldwide.

Sub-Saharan Africa remains by far the worst-affected region and is home to two-thirds of all people living with HIV.

In 2005 Bush launched a anti-malaria campaign aimed at funding pesticide spraying, handouts of bed nets and provision of anti-malarial drugs.

Malaria remains a leading killer worldwide, claiming more than one million lives every year, most of them in Africa.

The mosquito-borne illness is the number one cause of death in children under the age of five, causing one death every 30 seconds.


'"/>




Page: 1

Related medicine news :

1. Skin Cancer Tumour Removed from Laura Bushs Leg
2. Laura Bush Makes Light of Cancer News
3. Malaria strikes Munger tribals
4. Sponging Cattle betters spraying in eradicating Malaria
5. Gene researchers make Malaria-resistant mosquito
6. More Treatment Options For Malaria
7. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
8. Jharkhand reports 13,000 Malaria cases
9. Researchers Discover Protein That Causes Malaria
10. Malarial gene ascertained
11. Artesunate Is Better For Malaria Than Quinine
Post Your Comments:
(Date:5/15/2008)...-869 to be Promising in Targeting Cancer Cells, ...TT PARK, Ill., May 15 /PRNewswire-FirstCall/ -- Ab... trial data of several investigative,compounds in ...rican,Society of Clinical Oncology (ASCO) Annual M...ntations include ABT-263, a Bcl-2 family protein,a...
(Date:5/15/2008)...inhua-PRNewswire-FirstCall/ -- China Yingxia,Inter...Yingxia" or "the,Company"), a leading provider in ...ent, manufacture and distribution of organic nutri...re products in the People,s Republic,of China ("PR...first,quarter ended March 31, 2008., First Quar...
(Date:5/15/2008)... goal of tailoring cancer treatment for each indiv...l Center today presented a study suggesting a simp...s treatment efficacy for patients with metastatic ...ometimes months to determine if a particular cance...ng to observe any significant radiographic changes...
(Date:5/15/2008)...n called IGF-1R in patients with gastrointestinal ...ient would be less responsive to the drug imatinib...K. Godwin, Ph.D., a researcher at the Fox Chase Ca...have shown that GIST cells, especially Gleevec-res...lopment for treatment-resistant breast cancer, a f...
Breaking Medicine News(10 mins):Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Protein predicts Gleevec resistance in gastrointestinal tumors 2
...cipate seizures in children with epilepsy.The most...udy was // licking, often of the face, followed b...ctive" behavior without aggression. In previous st...that licking may abort or even prevent their seizu...
...feeling sick and with a number of other side effec...tment // and all they go through with it may not e...ng a new, more targeted approach to delivering che... aggressive way available to deliver chemotherapy ...
...icles and cause prostate cancer cells to grow. Low...shrink or grow more slowly. However, hormone thera... other treatments such as surgery or radiation are...common treatment for prostate cancer significantly...
...atment proves to be the best option to substantial...gery to remove part of the affected vein in additi...new treatment option for leg ulcers .Surgery did n...ms of venous ulcer healing, but recurrence rates w...
Other Medicine News:
(Date:5/15/2008)...trated in Blacks, Hispanics/Latinos, People ...ARSIPPANY, N.J., May 15 /- Daiichi Sa... the American Society of,Hypertension,s Twenty- Th...leans demonstrated that the powerful combination d... safely and effectively helped,patients across sev...
(Date:5/15/2008)...15 /- Ergonex Pharma today,announced ...n (FDA) has,granted orphan drug designation to Ter...ertension (PAH). Terguride is currently being eval...e., "The FDA,s grant of orphan drug designation t... development program by offering regulatory,clini...
(Date:5/15/2008)... for an Antiplatelet Therapy that, Combined, with ... of Plavix/Iscover and Aspirin, According to a...s., May 15 /- Decision Resources, one...s for pharmaceutical and,healthcare issues, finds ...rovement in patient compared to Sanofi-Aventis/Bri...
(Date:5/15/2008)...Annual Meeting of The American Society of ..., IRVINE, Calif., May 15 /...today announced the presentation of updated data,f...murtide (L-MTP-PE) in,patients with lung metastase...a rare and often fatal bone tumor that typically a...
Breaking Medicine Technology:Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 1599 1Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 1599 2Personalized Medicine The Genomic Revolution in Cardiac Care 330 1Personalized Medicine The Genomic Revolution in Cardiac Care 330 2Personalized Medicine The Genomic Revolution in Cardiac Care 330 3Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT 1001 for the Treatment of Celiac Disease 326 1Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT 1001 for the Treatment of Celiac Disease 326 2Early Human Like Skeletons Are First Outside of Africa 1595 1Early Human Like Skeletons Are First Outside of Africa 1595 2Early Human Like Skeletons Are First Outside of Africa 1595 3
...tection Observed Prior to or Up to 24 Hours After,...7 /PRNewswire/ -- Targanta,Therapeutics Corporatio...demonstrating oritavancin as a potential therapy f...cterium which causes anthrax,an acute infectious ...glycopeptide antibiotic for the treatment of serio...
...-(BUSINESS WIRE)--May 25, 2007 - GTx, Inc., (NASDA... Phase II proof of,concept clinical trial of Ostar...ial evaluating ACAPODENE(R) (toremifene citrate) 8... androgen,deprivation therapy (ADT) will be presen...rican Society of Clinical Oncology being,held June...
Other Medicine Technology:Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 2Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 3Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 4GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum.
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously.
...nesthesia and Respiratory Products, ,Westmed desi...ical devices for Anesthesia and Respiratory profes...products that enhance the clinician's ability to d...ention to the bottom line. , ,Our web site is des...
...he age of 3 can choose either the PARI LC PLUS®...applies to both:, ,Maximize aerosol output when t...n the patient exhales using two one-way valves. Ba... nebulizer. The result is a high percentage of par...
Medicine Products: